Candidate vaccines for immunotherapy in HIV

HIV Medicine

Volumn 2, Issue 4, 2001, Pages 260-265

  Gotch, F M ^a,b   Imami, N ^a   Hardy, G ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HIV; Immune response; Vaccines

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN;

ACUTE DISEASE; ARTICLE; CONTROL; CONTROLLED STUDY; DISEASE COURSE; DRUG SYNTHESIS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

ACUTE DISEASE; AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE PROGRESSION; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; PATIENT SELECTION; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035203135     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00077.x     Document Type: Article

References (42)

1. AIDS vaccines show promise after years of frustration
2. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators
3. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
4. Immune restoration with antiretroviral therapies: Implications for clinical management
5. Alterations in the immune response of HIV infected subjects treated with an HIV-specific protease inhibitor - Ritonavir
6. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in HIV advanced disease
7. Long lasting recovery in CD4 T-cell function and viral load reduction after HAART in advanced disease
8. Dramatic rise in plasma viraemia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
9. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
10. Naïve and memory CD4+ T-cells and T-cell receptor (TCR) V repertoire dynamics are independent of the levels of viraemia following HIV sero-conversion
11. New concepts in the immunopathogenesis of HIV infection
12. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
13. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
14. Long-term HIV-1 infection without immunologic progression
15. Even individuals considered as long-term non-progressors show biological signs of progression after 10 years of HIV infection
16. Loss of CD4+ T cell proliferative ability but not loss of HIV type 1 specificity equates with progress to disease
17. HIV specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function
18. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long term non-progressors
19. The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children
20. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
21. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
22. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
23. Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology
24. Loss of peripheral blood dendritic cell sub-populations in HIV-1 seropositive Ugandan individuals
25. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
26. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normald immune parameters and limited viral reservoir
27. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp 120-depleted HIV-1 in incomplete Freund's adjuvant
28. Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV type 1-seropositive individuals
29. Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen
30. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope sunbunit vaccine, on progression of immunodeficiency
31. Phase II controlled trial of post-exposure immunization with recombinant gp 160 versus antiretroviral therapy in asymptomatic HIV-1 infected adults
32. Safety and immunogenicity study of vcp1452/rgp160 therapeutic vaccines in patients treated with HAART for over 2 years
33. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
34. Discontinuation of HAART after a course of therapeutic vaccination with ALVAC1452 and rgp 160 may be associated with delayed viral rebound kinetics
35. Pre-clinical development of a multi-CTL epitope-based prime MVA boost vaccine for AIDS
36. Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector
37. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
38. Immune responses in asymptomatic HIV-1 infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
39. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy
40. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and TH1-biaising cytokines
41. Escape of human immunodeficiency virus from immune control